de Lusignan Simon, McGovern Andrew, Hinton William, Whyte Martin, Munro Neil, Williams Emily D, Marcu Afrodita, Williams John, Ferreira Filipa, Mount Julie, Tripathy Manasa, Konstantara Emmanouela, Field Benjamin C T, Feher Michael
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Department of Clinical and Experimental Medicine, University of Surrey, Guildford, UK.
Diabetes Ther. 2022 Oct;13(10):1789-1809. doi: 10.1007/s13300-022-01306-z. Epub 2022 Sep 2.
Initiation of injectable therapies in type 2 diabetes (T2D) is often delayed, however the reasons why are not fully understood.
A mixed methods study performed in sequential phases. Phase 1: focus groups with people with T2D (injectable naïve [n = 12] and experienced [n = 5]) and healthcare professionals (HCPs; nurses [n = 5] and general practitioners (GPs) [n = 7]) to understand their perceptions of factors affecting initiation of injectables. Phase 2: video-captured GP consultations (n = 18) with actor-portrayed patient scenarios requiring T2D treatment escalation to observe the initiation in the clinical setting. Phase 3: HCP surveys (n = 87) to explore external validity of the themes identified in a larger sample.
Focus groups identified patients' barriers to initiation; fear, lack of knowledge and misconceptions about diabetes and treatment aims, concerns regarding lifestyle restrictions and social stigma, and feelings of failure. Facilitators included education, good communication, clinician support and competence. HCP barriers included concerns about weight gain and hypoglycaemia, and limited consultation time. In simulated consultations, GPs performed high-quality consultations and recognised the need for injectable initiation in 9/12 consultations where this was the expert recommended option but did not provide support for initiation themselves. Survey results demonstrated HCPs believe injectable initiation should be performed in primary care, although many practitioners reported inability to do so or difficulty in maintaining skills.
People with T2D have varied concerns and educational needs regarding injectables. GPs recognise the need to initiate injectables but lack practical skills and time to address patient concerns and provide education. Primary care nurses also report difficulties in maintaining these skills. Primary care HCPs initiating injectables require additional training to provide practical demonstrations, patient education and how to identify and address concerns. These skills should be concentrated in the hands of a small number of primary care providers to ensure they can maintain their skills.
2型糖尿病(T2D)患者开始注射治疗的时间往往会延迟,但其原因尚未完全明确。
采用分阶段进行的混合方法研究。第一阶段:对T2D患者(初用注射药物者[n = 12]和有经验者[n = 5])以及医疗保健专业人员(HCPs;护士[n = 5]和全科医生[GPs][n = 7])进行焦点小组访谈,以了解他们对影响开始注射治疗因素的看法。第二阶段:对由演员扮演患者场景、需要升级T2D治疗的全科医生会诊进行视频记录(n = 18),以观察临床环境中的起始治疗情况。第三阶段:对HCPs进行调查(n = 87),以在更大样本中探索所确定主题的外部有效性。
焦点小组确定了患者开始治疗的障碍;对糖尿病和治疗目标的恐惧、知识缺乏和误解、对生活方式限制和社会耻辱感的担忧以及失败感。促进因素包括教育、良好沟通、临床医生支持和能力。HCPs的障碍包括对体重增加和低血糖的担忧以及会诊时间有限。在模拟会诊中,全科医生进行了高质量的会诊,并在9/12次会诊中认识到需要开始注射治疗(这是专家推荐的选择),但他们自己并未提供开始治疗的支持。调查结果表明,HCPs认为应在初级保健中开始注射治疗,尽管许多从业者报告无法这样做或难以维持相关技能。
T2D患者对注射治疗有不同的担忧和教育需求。全科医生认识到需要开始注射治疗,但缺乏实用技能和时间来解决患者的担忧并提供教育。初级保健护士也报告在维持这些技能方面存在困难。开始注射治疗的初级保健HCPs需要额外培训,以提供实际演示、患者教育以及如何识别和解决问题。这些技能应集中在少数初级保健提供者手中,以确保他们能够维持这些技能。